485 Results (Page 1 of 20)
China Markets Research Reports
China Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Analysis
China's Paroxysmal Nocturnal Hemoglobinuria (PNH) therapeutics market is expected to grow from $297 Mn in 2022 to $721 Mn in 2030 with a CAGR of 11.70% for the year 2022-30. Since eculizumab, a drug used to treat PNH is now available in China, many patients are starting to express interest in using targeted therapy to treat rare diseases. The market for PNH therapies in China is anticipated to increase as a result of this tendency. The market is segmented by therapy, diagnostic test, and distribution channels. Some key players in this market include Sinopharm Group, Shanghai Pharmaceuticals, Jiangsu Hengrui Medicine, Amgen, CSL Behring, and Bioverativ.
China ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis
China's Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is projected to grow from $2.37 Bn in 2022 to $4.73 Bn in 2030 with a CAGR of 9% for the year 2022-30. A more significant proportion of the young population and therefore an increasing prevalence of ADHD among children in China are driving the growth of the market. The China ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Shanghai Fosun Pharmaceutical, Huadong Medicine, and Adlon Therapeutics are the key players in the market.
China Contact Lenses Market Analysis
China Contact Lenses Market was valued at $1,377.84 Mn in 2023 and is predicted to grow at a CAGR of 10.4% from 2023 to 2030, to $2,754.11 Mn by 2030. The key drivers of this industry include rising disposable income, growing prevalence of myopia, and shifting preference towards daily disposables. The industry is primarily dominated by Bausch and Lomb, CooperVision, Alcon Vision, and Essilor among others.
China Primary Hyperoxaluria (PH) Therapeutics Market Analysis
China Primary Hyperoxaluria (PH) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. One of the key factors propelling the growth of the hyperoxaluria drug market is the rise in the number of persons with the condition worldwide. The regulatory body's extension of special designations and rising consumer demand for medications including thiazide diuretics, calcium oxalate urinary inhibitors, and others to address a variety of health issues both contribute to the market's quick growth. Major global players in Primary Hyperoxaluria (PH) Therapeutics Market are Allena Pharmaceuticals, Inc., Intellia Therapeutics, Inc., OxThera, Dicerna Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Inc., Pfizer Inc., and Sanofi.
China Medical and Diagnostic Laboratory Service Market Analysis
This report presents a strategic analysis of the China Medical and Diagnostic Laboratory Service Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the China Medical and Diagnostic Laboratory Service Market, offering unmatched value, accuracy, and expert insights.
China Mucopolysaccharidosis I (MPS-I) Therapeutics Market Analysis
China Mucopolysaccharidosis I (MPS-I) therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Rising consumer awareness, new drug approvals, enticing reimbursement plans, an established healthcare system, and the presence of sizable market competitors all drive the market for treating Mucopolysaccharidosis I. Major global players in this market are Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics, Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.
China Virtual Clinical Trials Market Analysis
This report presents a strategic analysis of the China Virtual Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the China Virtual Clinical Trials Market, offering unmatched value, accuracy and expert insights.
China Antiviral Drugs Market Analysis
This report presents a strategic analysis of the China Antiviral Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the China Antiviral Drugs Market, offering unmatched value, accuracy and expert insights.
China Dental Caries Detectors Market Analysis
The China Dental Caries Detectors Market was valued at $18.3 Mn in 2023 and is predicted to grow at a CAGR of 10.4% from 2023 to 2030, to $36.7 Mn by 2030. China Dental Caries Detectors Market is growing due to the Rising prevalence of dental caries, Economic Growth, Increasing Disposable Income, and Advanced imaging and diagnostics. The market is primarily dominated by players such as Weizhou, Shanghai Jahwa, Smile 360, Pacific Dental Services, Dental Services Group, Sirona Dental Systems, Dentsply Sirona, KaVo Kerr, Ivoclar Vivadent, Planmeca Oy, Adec Technologies, 3M ESPE, Morita Corporation, Woodpecker Medical Instruments Co., Softdent.
China Clinical Nutrition for Diabetes Care Market Analysis
The China Clinical Nutrition for Diabetes Care Market was valued at $172.83 Mn in 2023 and is predicted to grow at a CAGR of 6.28% from 2023 to 2030, to $264.72 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Nutreco, Sanofi SA, Danone Nutricia, and Abbott Nutrition among others.
China Pharmacy Automation Device Market Analysis
The China Pharmacy Automation Device Market was valued at $442.1 Mn in 2023 and is predicted to grow at a CAGR of 11.4% from 2023 to 2030, to $941.3 Mn by 2030. China Pharmacy Automation Device Market is growing due to Reducing Human Errors, Increasing adoption among end-users and Rising Demand for Pharmaceuticals. The market is primarily dominated by players such as Shanghai Fosun Pharmaceutical, WuXi AppTec Co, Amerisource Bergen Corporation, Omnicell, Inc., McKesson Corporation; Pearson Medical Technologies, Baxter; Talyst, LLC, Scriptpro LLC.
China Cardiac Pacemakers Market Analysis
The China Cardiac Pacemakers Market was valued at $325.32 Mn in 2023 and is predicted to grow at a CAGR of 4.7% from 2023 to 2030, to $448.68 Mn by 2030. The key drivers of this industry include an increasing aging population, healthcare expenditure, and growing awareness. The industry is primarily dominated by players such as Abbott Laboratories, Biotronik, Boston Scientific, and Medtronic among others.
China Clinical Nutrition for Cancer Care Market Analysis
The China Clinical Nutrition for Cancer Care Market was valued at $452.6 Mn in 2023 and is predicted to grow at a CAGR of 6.54% from 2023 to 2030, to $705.2 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, increasing risk of malnutrition in oncology patients, and advancements in nutritional products. The prominent players of the China Clinical Nutrition for Cancer Care Market are MediFood, Nestlé Health Science, Abbott Nutrition, B. Braun Melsungen AG, and Fresenius Kabi, among others.
China Gram-Negative Infection Therapeutics Market Analysis
The China Gram-Negative Infection Therapeutics Market was valued at $1195.84 Mn in 2023 and is predicted to grow at a CAGR of 7.4% from 2023 to 2030 to $1970.9 Mn by 2030. The key drivers of this market expansion include public health initiatives, the rising incidence of gram-negative infections, and the growing demand for effective treatments. The leading companies operating in this market in China include Merck & Co., Inc. and AstraZeneca, among others.
China Home Infusion Therapy Market
The China Home Infusion Therapy Market was valued at $2890.7 Mn in 2023 and is predicted to grow at a CAGR of 9.6% from 2023 to 2030, to $5491.4 Mn by 2030. The key drivers of the market include rising prevalence of chronic diseases, expanding geriatric population, and technological advancements. The prominent players of the China Home Infusion Therapy Market are Poly Medicure, Baxter International, ICU Medical (Smiths Medical), Becton, Dickinson and Company (BD), and Fresenius Kabi, among others.
China Hepatitis A Therapeutics Market Analysis
The China Hepatitis A Therapeutics Market was valued at $59.26 Mn in 2023 and is predicted to grow at a CAGR of 3.7% from 2023 to 2030 to $76.42 Mn by 2030. Major factors propelling this market forward encompass periodic outbreaks, vaccination programs, and increased awareness. Leading players in this sector include Biological E Ltd, Boryung Pharmaceutical Co Ltd, and others.
China Leukocyte Adhesion Deficiency (LAD-I) Market Analysis
China Leukocyte Adhesion Deficiency (LAD-I) therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. An uncommon genetic condition called leukocyte adhesion deficiency (LAD-I) impairs the immune system's capacity to combat infections. There is currently no cure for LAD-I, and there are few effective treatments available. To fill this unmet medical need, new medicines are becoming more and more popular. Vertex Pharmaceuticals, Orpha Labs, Avalo Therapeutics, Inc., Rocket Pharmaceuticals, Inc., Aspen Neuroscience, Magenta Therapeutics, Rubius Therapeutics, Enochian Biosciences, Sana Biotechnology, and Sigma-Aldrich are major global players.
China Glioblastoma Multiforme Therapeutics Market Analysis
China Glioblastoma Multiforme Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The most aggressive primary brain tumour is glioblastoma, also known as glioblastoma multiforme (GBM), which makes up for 15% of all intracranial neoplasms and 49% of malignant brain tumours. GBM is more common and has a worse prognosis as people age. It is still very difficult to increase the overall survival (OS) and progression-free survival (PFS) of GBM patients. Consequently, the GBM market has drivers. It is still very difficult to increase the overall survival (OS) and progression-free survival (PFS) of GBM patients. Global The following companies are significant players in the market: Arbor Pharmaceuticals, LLC, Amneal Pharmaceuticals, Karyopharm Therapeutics, Inc., Sumitomo Dainippon Pharma Oncology, Inc., Merck & Co., Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., Amgen, Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd. (Boston Biomedical, Inc.)
China Hereditary Angioedema Therapeutics Market Analysis
China Hereditary Angioedema Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. A uncommon genetic condition known as hereditary angioedema (HAE) is characterised by recurrent episodes of swelling in different body areas. It is brought on by a lack or malfunction of certain proteins involved in controlling the immune response. The regulatory authorities have designated numerous HAE therapies as orphan drugs as a result of this classification, pharmaceutical companies are given some incentives including financial advantages and prolonged exclusivity, which may promote investment in HAE R&D. The increasing prevalence and diagnosis of HAE around the world have been driving the growth of the global market for HAE therapies. This trend offers pharmaceutical businesses the chance to increase their market share, make research and development investments, and introduce novel treatments to various geographic areas. Hereditary angioedema therapies are being developed and produced by a number of international pharmaceutical companies (HAE). Takeda Pharmaceutical Company Limited, Inc., CSL Behring, Pharming Group NV, Ionis Pharmaceuticals, Pharvaris, Dyax Corp., Shire (now a part of Takeda), Attune Pharmaceuticals, Prometic Life Sciences Inc., KalVista Pharmaceuticals, and Biocryst are some of these organisations.
China Infectious Disease Drugs Market Analysis
China Infectious Disease Drugs Market valued at $9.54 Bn in 2023, projected to reach $14.14 Bn by 2030 with a 5.77% CAGR. The industry is being driven by rising healthcare costs, technological innovation and advancements, and an aging population. The market is dominated by key players like Shanghai Fosun Pharmaceuticals, Sinovac Biotech, GlaxoSmithKline plc, AstraZeneca, AbbVie Inc., Gilead Sciences, Merck & Co., F. Hoffman-La Roche Ltd., Boehringer Ingelheim International GmbH, and Janssen Pharmaceuticals.
China Guillain-Barre Syndrome (GBS) Drugs Market Analysis
China Guillain-Barre Syndrome (GBS) drugs market is projected to grow from $40.2 Mn in 2022 to $67.54 Mn by 2030, registering a CAGR of 6.7% during the forecast period of 2022-2030. The market for Guillain-Barre Syndrome (GBS) drugs is growing rapidly as a result of increase in the incidence and prevalence of the guillain-barre syndrome, advancements in technology and development in healthcare, support and funding by governments globally, rise in the geriatric population and increase in the prevalence of chikungunya and immune diseases like multiple sclerosis , increase in the approvals of immunoglobulins by regulatory bodies and increase in research and development activities by pharmaceutical companies. Alexion Pharmaceuticals Inc., Annexon Inc., Cellenkos Inc., Cresence AS, Akari Therapeutics Plc, Chugai Pharmaceutical Co Ltd are the key market players operating in global gullian barre syndrome drugs market.
China Paroxysmal Noctural Hemglobinuria (PNH) Therapeutics Market Analysis
China's Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market is projected to grow from $0.23 Bn in 2022 to $0.67 Bn by 2030, registering a CAGR of 14.6% during the forecast period of 2022-2030. The market for Paroxysmal Nocturnal Hemoglobinuria Therapeutics is being driven by reasons like the rise in blood and bone marrow abnormalities, population ageing, rising disposable income, unmet demand for PNH treatment, and technological improvements in stem cell transplantation. Major global players in Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market are Achillion Pharmaceuticals Akari Therapeutics Alexion Pharmaceuticals Amgen Inc. Apellis Pharmaceuticals F. Hoffmann-La Roche AG. GE Healthcare Johnson & Johnson Ra Pharmaceuticals Regeneron Pharmaceuticals, Inc. Takeda Pharmaceutical Company Limited (Shire Plc) Thermo Fisher Scientific Inc.
China Autoimmune Hemolytic Anemia Drugs Market Analysis
China Autoimmune Hemolytic Anemia Drugs Market is projected to grow from $122.19 Bn in 2022 to $236.42 Bn by 2030, registering a CAGR of 8.6% during the forecast period of 2022-30. A rise in the prevalence of certain autoimmune illnesses and malignancies, as well as increased funding for research into innovative interventions and growing demand for novel therapies, are all contributing to an increase in the market for medications to treat autoimmune hemolytic anaemia. Major global players in Autoimmune Hemolytic Anemia Drugs Market are F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Zydus Cadila, Vertice Pharma, Concord Biotech, Alkem Labs, Dr. Reddy's Laboratories Ltd, Jubilant Life Sciences Ltd, Strides Pharma Science Limited, Mylan N.V., Novartis AG, Sanofi, Rigel Pharmaceuticals Inc, Incyte Corporation, Alexion Pharmaceuticals, Apellis Pharmaceuticals.
China Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market Analysis
This report presents a strategic analysis of the China Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the China Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market, offering unmatched value, accuracy, and expert insights.
China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis
China Duchenne Muscular Dystrophy (DMD) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A genetic condition known as Duchenne muscular dystrophy (DMD) is characterised by advancing muscle weakness and degeneration as a result of changes to a protein called dystrophin, which aids in maintaining healthy muscle cells. The market is expanding as a result of favourable government initiatives that provide appropriate reimbursement policies and promote target-specific treatments. Rapid urbanisation, better medical infrastructure, the emergence of product premiumization, and rising disposable incomes among the general populace are a few other drivers generating profitable growth potential in the industry. Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, Italfarmaco, Santhera Pharmaceuticals, and many more are Global companies in the DMD Therapeutics market.